Intrathecal use of amikacin: a case report

Meningitis caused by Acinetobacter baumannii is rare and are mostly hospital acquired after neurosurgical procedure. We report a case of a 40-year old man was admitted to the intensive care unit due to subarachnoid haemorrhage. Our patient developed a ventriculitis due to A.baumannii treated successfully with sulbactam IV and intrathecal amikacin.

Risk factors for multi-drug resistant Acinetobacter baumannii nosocomial infection.

OBJECTIVE: To assess factors associated with multi-drug resistant Acinetobacter baumannii (MDR-AB) nosocomial infection. MATERIAL AND METHOD: This hospital-based case-control study was conducted in patients admitted to Siriraj Hospital, Bangkok, Thailand between January 1, 2005 and December 31, 2005. The study population consisted of 155 cases with MDR-AB nosocomial infection and 310 controls without nosocomial infection. The cases were matched with controls by age and ward of admission with a ratio of 1:2. RESULTS: The average age of the present study population was 63.5 +/- 18.7 years among cases and 62.9 +/- 18.2 years among controls. The mean of length of stay in hospital among cases was 4.9 +/- 1.4 weeks and controls 1.8 +/- 1.0 weeks. The most common site of MDR-AB nosocomial infection was lower respiratory tract (74.8%). The antimicrobial susceptibility of MDR-AB was 3.9% to cetriaxone and 42.1% to cefoperazone/sulbactam. Multiple logistic regression analysis showed the following associated factors with MDR-AB nosocomial infection: duration of admission prior to MDR-AB nosocomial infection > 1 week (OR = 2.06; 95% CI 1.09-3.89), indwelling urinary catheter > 1 week (OR = 8.24; 95% CI 3.81-17.82), mechanical ventilation > 1 week (OR = 5.73; 95% CI 2.96-11.10), central venous line > 1 week (OR = 3.29; 95% CI 1.48-7.31), nasogastric intubation > 1 week (OR = 6.22; 95% CI 3.24-11.93), prior administration of 3rd-4th generation cephalosporins (OR = 1.80; 95% CI 1.04-3.13), metrodazole (OR = 2.59; 95% CI 1.21-5.56), and piperacillin-tazobactam (OR = 4.68; 95% CI 1.93-11.32). CONCLUSION: A case-control study in medical and surgical patients in Siriraj Hospital in 2005 revealed risk factors for AB nosocomial infection. Prolonged admission of more than 2 weeks, use of devices, and prior treatment with certain antimicrobials were found to be significant risk factors for the infection. To reduce the infection, strict infection control measures must be applied to the patients with these risk factors. Education to medical personnel and enforcement of infection control practices are all needed to reduce antimicrobial resistant bacterial nosocomial infection.

Comportamiento de acinobacter en los procesos infecciosos de los pacientes ingresados al HEALF de enero 2004 a diciembre de 2005 / Acinobacter behavior in the infectious processes of the patients entered the HEALF of January 2004 to December of 2005

El trabajo comportamiento de acinetobacter en los procesos infecciosos de pacientes ingresados al HEALF de enero de 2004- diciembre de 2005, se realizó con el objetivo de conocer el comportamiento de esta bacteria en nuestro medio ya que el acinetobacter ha surgido como un importante microorganismo a nivel intrahospitalario y uno de los mayores problemas de la infecciones producidas por esta bacteria es su tratamiento, por su amplia multiresistencia y por las pocas alternativas terapéuticas disponibles en la actualidad. Dicho estudio es descriptivo, de serie de casos. Para alcanzar este objetivo se estudiaron 452 pacientes a los que se aisló 528 Acinetobacter. Los procesos infewcciosos más frecuentes fueron: Sepsis de Herida Quirúrgica, Neumonías y Traqueóbronquitis. Los servicios más afectados fueron: Medicina Interna y de esta, la sala de UCI (Unidad de cuidados intensivos), Neurocirugía, principalmente lka sala de Neurocirugía Intermedios y cirugía plástica principalmente la sala de quemados. Según los resultados de Antibiogrma se encontró un alto grado de resistencia de la bacteria a los antibióticos disponibles en la Lista Básica de Medicamentos como son: Ceftriazona, Ampicilina, Amikacina, Ceftazidima y en menor grado de resistencia a los Carbapemenes (Imipenem, Meropenem)...>